- Research article
- Open Access
A comparison of in vitro properties of resting SOD1 transgenic microglia reveals evidence of reduced neuroprotective function
- Siranush A Sargsyan1Email author,
- Daniel J Blackburn2,
- Siân C Barber2,
- Julian Grosskreutz3,
- Kurt J De Vos4,
- Peter N Monk†5 and
- Pamela J Shaw†2
© Sargsyan et al; licensee BioMed Central Ltd. 2011
- Received: 8 May 2011
- Accepted: 23 September 2011
- Published: 23 September 2011
Overexpression of mutant copper/zinc superoxide dismutase (SOD1) in rodents has provided useful models for studying the pathogenesis of amyotrophic lateral sclerosis (ALS). Microglia have been shown to contribute to ALS disease progression in these models, although the mechanism of this contribution remains to be elucidated. Here, we present the first evidence of the effects of overexpression of mutant (TG G93A) and wild type (TG WT) human SOD1 transgenes on a set of functional properties of microglia relevant to ALS progression, including expression of integrin β-1, spreading and migration, phagocytosis of apoptotic neuronal cell debris, and intracellular calcium changes in response to an inflammatory stimulus.
TG SOD1 G93A but not TG SOD1 WT microglia had lower expression levels of the cell adhesion molecule subunit integrin β-1 than their NTG control cells [NTG (G93A) and NTG (WT), respectively, 92.8 ± 2.8% on TG G93A, 92.0 ± 6.6% on TG WT, 100.0 ± 1.6% on NTG (G93A), and 100.0 ± 2.7% on NTG (WT) cells], resulting in decreased spreading ability, with no effect on ability to migrate. Both TG G93A and TG WT microglia had reduced capacity to phagocytose apoptotic neuronal cell debris (13.0 ± 1.3% for TG G93A, 16.5 ± 1.9% for TG WT, 28.6 ± 1.8% for NTG (G93A), and 26.9 ± 2.8% for NTG (WT) cells). Extracellular stimulation of microglia with ATP resulted in smaller increase in intracellular free calcium in TG G93A and TG WT microglia relative to NTG controls (0.28 ± 0.02 μM for TG G93A, 0.24 ± 0.03 μM for TG WT, 0.39 ± 0.03 μM for NTG (G93A), and 0.37 ± 0.05 μM for NTG (WT) microglia).
These findings indicate that, under resting conditions, microglia from mutant SOD1 transgenic mice have a reduced capacity to elicit physiological responses following tissue disturbances and that higher levels of stimulatory signals, and/or prolonged stimulation may be necessary to initiate these responses. Overall, resting mutant SOD1-overexpressing microglia may have reduced capacity to function as sensors of disturbed tissue/cellular homeostasis in the CNS and thus have reduced neuroprotective function.
- Amyotrophic Lateral Sclerosis
- Mutant SOD1
- Amyotrophic Lateral Sclerosis Case
- SOD1 G93A
- Mixed Glial Culture
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by selective demise of upper motor neurons in the motor cortex and lower motor neurons in the brainstem and spinal cord [1, 2]. Disease onset occurs in mid-life (50 to 60 years of age) and is followed by a rapid (2 to 5 years), progressive failure of the neuromuscular system and death. Although the aetiology of ALS is yet to be fully elucidated, several factors are likely to contribute to motor neuron injury, including excitotoxic and oxidative motor neuron damage, protein aggregation, impaired axonal transport, mitochondrial dysfunction, and non-cell autonomous damage mediated through glial cells - astrocytes and microglia [3, 4]. Most of the current insights into disease pathogenesis come from studies on animal models overexpressing mutant forms of Cu/Zn superoxide dismutase 1 (SOD1) . Autosomal dominant inheritance of mutant SOD1 accounts for 20 percent of familial ALS (FALS) cases, or 2 percent of all ALS cases [6, 7]. Overexpression of mutant forms of SOD1, including G93A, G37R and G85R mutant SOD1, in animal models faithfully replicates pathological features of the human disease [8–10]. Motor neurons expressing mutant SOD1 can escape disease if surrounded by a sufficient number of normal non-neuronal cells . Conversely, normal motor neurons surrounded by mutant SOD1-containing non-neuronal cells developed signs of cellular injury with the development of ubiquitinated protein deposits . Selectively reducing the levels of mutant SOD1 in motor neurons delayed early disease progression and extended lifespan by a mean of 22 percent (64 days). In contrast, reducing mutant SOD1 expression in microglia, the major immune cell of the CNS with a monocyte/macrophage phenotype, had no effect on onset and early disease but showed a large protective effect in late stage disease and ameliorated disease progression with a mean extension of survival of 99 days . Moreover, a significant slowing of disease progression was observed in double transgenic G93A-SOD1/PU.1-/- mice when the mice received wild type but not G93A-SOD1 bone marrow transplant .
While the mechanisms of microglial disease propagation remain to be fully elucidated, studies indicate that mutant SOD1-overexpressing microglia may acquire an exaggerated inflammatory phenotype and neurotoxic properties following sustained activation. Low levels of inflammatory mediators are present in the cerebrospinal fluid of ALS patients [14–16] and activated microglia are detected in the CNS  and in the neighbourhood of degenerating motor neurons in post-mortem studies of the human disease . SOD1 transgenic mouse and rat models of ALS also display signs of an inflammatory response in the CNS at all stages of the disease. Prior to the clinical signs of disease onset, microglia are in an early state of activation, and elevated levels of inflammatory mediators such as interleukin (IL)-6 can be detected [19, 20]. With the onset of symptoms and motor neuron cell death, fully activated (or reactive) microglia are present in the CNS and microglial production of the pro-inflammatory cytokine, tumour necrosis factor (TNF)-α has been demonstrated [21–24]. Elevated levels of TNF-α, monocyte chemoattractant protein (MCP)-1, macrophage-colony stimulating factor (M-CSF), interferon (IFN)-γ and transforming growth factor (TGF)-β [15, 23, 25, 26] and an increase in cyclooxygenase (COX)-2 activity and prostaglandin (PG) E2 levels [14, 15, 23, 25, 27] have been shown in mutant SOD1 transgenic mouse tissues and microglial cells. Administration of drugs such as minocycline, or inhibitors of COX-2 and peroxisome proliferator-activated receptor (PPAR), capable of reducing microglial activation, delayed both disease onset and progression in mutant SOD1 transgenic mice [28–31].
It is unknown whether microglia overexpressing the wild type form of human SOD1 can acquire altered functional properties. Overexpression of wild type SOD1 in animals did not reveal any overt pathology at four months of age  except signs of deficiency of muscle innervation and premature aging [33–36]. Thus, wild type SOD1 could also contribute to neuronal pathogenesis. For example, autopsy material from familial as well as sporadic ALS cases revealed Lewy body-like hyaline inclusions within motor neurons that immunoreacted with anti-SOD1 antibodies . Overexpression of wild type SOD1 in mutant SOD1 transgenic animals accelerated the disease course and shortened the lifespan of double transgenic animals . Additionally, wild type SOD1 acquired toxic properties similar to those of the mutant forms of SOD1 following oxidative damage . Therefore, it is possible that wild type SOD1-overexpressing microglia may also have altered cellular properties rendering the cells capable of propagating neuronal damage.
In healthy animals, microglia perform a surveillance function to maintain a physiologically healthy microenvironment . They accomplish this by sampling the surrounding tissue with numerous extruding and retracting processes . Alterations in the tissue microenvironment induce microglial migration to the site of damage, scavenging of extruded cellular or plasma proteins and clearance of damaged cell components through phagocytosis [41, 42]. These dynamic effector functions of microglia are dependent on the presence of diverse surface receptors, including cytokine, chemokine, immunoglobulin, and purinergic receptors [43, 44]. Efficient intracellular signalling, control of gene expression, and tightly regulated function of the actin cytoskeleton are also necessary for appropriate microglial effector responses [45, 46]. Interestingly, in vivo recordings of labelled microglia from SOD1 G93A-overexpressing mice revealed significantly increased microglial response towards laser-induced single axon transection at preclinical age (60 days) when compared to that in control mice, and a subsequent reduction in SOD1 G93A microglial response to the same injury with disease progression (90 and 120 days) .
The purpose of the current study was to investigate whether overexpression of the mutant SOD1 transgene (TG G93A) or the wild type SOD1 transgene (TG WT) in microglia could significantly alter their functional properties, potentially contributing to neurodegeneration and its propagation. Due to inherent differences between the two colonies of transgenic mice that we observed in our studies, we compared the differences between NTG and TG cells within colonies, and not between colonies. Specifically, we examined non-transgenic (NTG: NTG (G93A) and NTG (WT)) and SOD1-overexpressing transgenic (TG G93A and TG WT) microglial surface expression of integrin β-1 (a subunit of integrin cell adhesion molecules), the ability of microglia to spread on fibronectin-coated surfaces and to migrate over astrocytic monolayers, the ability to phagocytose apoptotic neuronal cell debris, and intracellular calcium changes in response to a pro-inflammatory stimulus, extracellular ATP. Mutant SOD1 caused the most marked changes in these functions but overexpression of wild type SOD1 also produced significant changes. Thus, it is essential to examine the effects of both mutant and wild-type SOD1 when investigating the role of microglial cells in ALS.
Reduced expression of integrin β-1 by TG G93A microglia
Reduced spreading ability of TG G93A microglia
Spreading and migration speeds are unaltered in TG G93A microglia but are increased in TG WT cells
Reduced ability of TG WT and TG G93A microglia to phagocytose apoptotic neuronal cell debris
Reduced intracellular calcium release in TG WT and TG G93A microglia following extracellular ATP stimulation
In the present study we compared an array of functional properties of transgenic microglia overexpressing wild type SOD1 or mutant SOD1 G93A to those of non-transgenic control cells.
Integrin β-1 (fibronectin receptor β) is involved in diverse cellular functions including cellular adhesion to extracellular matrix, focal adhesion, migration, actin polymerisation/assembly, and regulation of the cell cycle [48–50]. We observed only modestly reduced levels of integrin β-1 on TG G93A microglia when compared to the levels on NTG (G93A) cells. Also, the small sample size of TG WT and NTG (WT) microglia may have prevented the detection of differences in integrin β-1 expression levels in this cell population. Nonetheless, reduced levels of integrin β-1 on TG G93A microglia could lead to impaired adhesion, migration, phagocytosis, and proliferation. To test whether the former three functions were altered in TG G93A microglia, we examined microglial spreading on fibronectin-coated surface, migration on genotype-matched astrocytic monolayers, and phagocytosis of apoptotic neuronal cell debris. We observed that although expression of integrin β-1 was marginally reduced, and spreading ability impaired, in TG G93A cells, these changes did not affect the migration of TG G93A microglia, as the cells were capable of migrating on genotype-matched astrocytes at the same speed as NTG (G93A) cells. This observation may indicate that the slightly reduced levels of integrin β-1 expression on TG G93A microglia may have no significant impact on the cellular spreading and migration, or that additional receptor-ligand interactions compensate for reduced integrin β-1 expression and impaired spreading ability.
Our study also showed that overexpression of both transgenes affected microglial phagocytosis of apoptotic neuronal cell debris, an effect presumably unrelated to the reduced integrin β-1 expression. Microglial uptake of degenerating motor neuronal debris has been shown in vivo after injection of toxin ricin into rat facial nerve . Microglia were the primary cells to clear neuronal debris from degenerating neurons during development or after neuronal injury in adult animals [52, 53]. Efficient clearance of SOD1 aggregates significantly improved the disease course in ALS model mice . Moreover, persistence of destroyed tissue debris was capable of inducing and perpetuating CNS tissue inflammation [55, 56]. Thus, the impaired ability to phagocytose apoptotic neuronal debris by TG WT, and more so by TG G93A, microglia may contribute to disease exacerbation.
Overexpression of SOD1 G93A as well as wild type SOD1 altered the intracellular Ca2+ responses to extracellular ATP stimulation. Cellular responses to extracellular nucleotides are mediated via cell surface P2 purinoreceptors, now classified as metabotropic (P2Y) receptors that mediate signalling through G-proteins, and ionotropic (P2X) receptors that are directly coupled to non-selective cationic receptors allowing for influx of Ca2+ and Na+ and efflux of K+ . Physiologically, ATP-induced signalling attracts microglia to the site of injury or cellular damage resulting in microglial activation [42, 58]. Microglia express P2X4, P2X7, P2Y1, P2Y2, P2Y6 and P2Y12 receptors [59–62], and their stimulation initiates release of Ca2+ from intracellular stores. In addition, stimulation through P2X receptors induces non-selective ion exchange that may result is microglial depolarisation . Microglia from SOD1 G93A-overexpressing ALS mouse models were found to have an increased expression of P2X4, P2X7 and P2Y6 receptors and reduced ability to hydrolyse extracellular ATP . Moreover, prolonged (3 to 24 hours) stimulation with 30 μM ATP induced higher levels of COX-2 expression and elevated production of the pro-inflammatory cytokine TNF-α in SOD1 G93A microglia compared to NTG cells , demonstrating the exaggerated pro-inflammatory phenotype of SOD1 G93A microglia. However, during our experiments, short (1 min) stimulation of microglia with 10 μM ATP demonstrated that microglia overexpressing SOD1 G93A, or wild type SOD1, had a reduced initial increase in intracellular Ca2+ when compared to that in NTG cells, which suggests an alteration of calcium release from the endoplasmic reticulum. Thus, higher ATP levels, and/or prolonged stimulation by the nucleotide, may be necessary in order to elicit physiologically relevant responses from SOD1-overexpressing microglia, although overstimulation leads to exaggerated pro-inflammatory response from TG G93A microglia (Reference  and Additional file 3).
To summarise, it is well characterized that in ALS animal models activated microglia contribute to neurodegeneration through production of neurotoxic compounds following activation [13, 64] and acquisition of an exaggerated inflammatory phenotype [24, 26]. Here, we show evidence that SOD1 transgenic microglia have a reduced capacity to sense tissue disturbances under resting conditions. The affected functions in resting SOD1 microglia are a reduced ability to phagocytose apoptotic neuronal cell debris and an attenuated response to extracellular ATP stimulation. We propose that resting state microglia overexpressing SOD1 G93A, or wild type SOD1, may contribute to disease pathogenesis through loss of efficient tissue-protective functions. Also, caution must be used when ascribing alterations in microglial behaviour to mutant SOD1 expression. Our results indicate that wild-type SOD1 overexpression can alter some properties of microglia and should be an obligatory control in all experiments.
Microglia, the macrophages of the brain, are known to play vital physiological roles in maintaining healthy CNS tissue architecture and function. In ALS pathogenesis, microglia contribute to disease progression through continuous activation and secretion of multiple pro-inflammatory and neurotoxic mediators. Here, we present the novel findings that resting-state microglia overexpressing wild type or mutant SOD1 transgenes have reduced physiologic responses of apoptotic neuronal cell clearance and release of Ca2+ from intracellular stores upon ATP stimulation. Our findings indicate that transgenic SOD1 microglia may require higher concentrations of stimulatory factors to elicit physiologically-relevant functions, indicating reduced neuroprotective behaviour of TG microglia.
Primary microglial culture preparation
All animals were handled in accordance with the guidelines of the Animals (Scientific Procedures) Act 1986. Microglia were purified from mixed glial cultures as described . Briefly, the cortices of neonatal (1-2 days old) human mutant SOD1 G93A transgenic mice, human wild type SOD1 transgenic mice, and their nontransgenic (NTG) littermates (NTG (G93A) and NTG (WT), respectively) were stripped of meninges, washed and triturated in Hank's balanced salt solution with Ca2+/Mg2+ containing 0.04% trypsin (Sigma), 0.1 mg/ml collagenase (Calbiochem) and 0.05 mg/ml DNaseI (Sigma). After trituration, the single cells were pelleted and plated in complete medium [Dulbecco's modified Eagle's medium (DMEM; Cambrex Bioscience), 10% heat-inactivated foetal calf serum (FCS; BioSera), 100 units/ml penicillin and 100 mg/ml streptomycin (Gibco, Invitrogen)] at 60 000 cells/cm2 on poly-L-lysine (Sigma) coated coverslips. For the purification of microglia, the confluent cultures were subjected to shaking and mild trypsinisation [13, 65], which resulted in microglial cultures of more than 90% purity.
The cells were washed with phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde for 15 min and permeabilised with 0.1% Triton X-100. Non-specific binding was blocked with 5% FCS in PBS for 30 min. The cells were incubated with rat anti-mouse CD11b (Serotec), rat anti-mouse F4/80 (Serotec), or isotype control (Serotec) primary antibodies in blocking buffer at room temperature. After washing with PBS, cells were incubated with the goat anti-rat-fluorescein isothiocyanate (FITC) secondary antibody (Serotec) and, where needed, with conjugated Cy3-anti-glial fibrillary acidic protein (GFAP) antibody (Sigma) in blocking buffer. After washing, the nuclei were stained with 0.2 μg/ml Hoechst 33342 (Intergen) solution for 1 min and the coverslips mounted on glass sides in mounting medium (50% glycerol in PBS).
Measurement of integrin β-1 expression
Microglia isolated from mixed glial cultures were deposited into U-bottomed 96-well plates at 20 000 cells/well, washed in 200 μl fluorescence activated cell sorting (FACS) buffer (PBS containing 0.2% w/v bovine serum albumin (BSA) and 0.1% w/v sodium azide) and incubated with conjugated FITC-anti-mouse integrin β-1 (Biolegend) or FITC-isotype control antibody (Biolegend) in FACS buffer for 20 min on ice. Cell-associated mean fluorescence intensity (MFI) was detected using a BD FACSort (Becton Dickinson). The acquired geometric mean fluorescence values of isotype antibody-stained cells were subtracted from those of the FITC-integrin β-1 stained cells. The resultant values were then compared between respective NTG and TG cells, after counting the mean MFI of NTG cells as 100% (Additional file 1).
Isolated microglia were added to an imaging chamber containing a coverslip coated with 5 μg/ml of bovine fibronectin (Calbiochem) as a substrate. Cells were visualized under a × 40 oil immersion objective heated to 37°C with an objective heater (Bioptechs, Intracel) and the spreading of individual cells in phase contrast recorded by a time-lapse automation, using Openlab 3.7.1 software. After the cells touched the coated coverslip, the frames were captured every 5 s for a maximum of 15 min. The captured frames were analysed with ImageJ plugins to obtain cell surface area values for every frame. The cells were classified as "spreading" if they initiated cell surface area expansion (spreading) within first 100 s of recording. The cells were classified as "delayed" if they initiated cell surface area expansion after the first 100 s of recording. The cells were classified as "stationary" if they did not initiate cell surface area increase during the entire recording time. For every spreading cell, the cell surface area values of the expanding (spreading) phase were plotted against the time taken to reach those values, and the speed of spreading was deduced from this relationship using GraphPad Prism 5.0 linear regression analysis.
Mixed glial cultures in T25 flasks (Croning) were placed in a microscope chamber equilibrated to 37°C, 5% CO2, (LEICA Microsystems AF6000LX microscope with environmental control) for time-lapse recordings. A × 10 objective field of cells was captured every 3 min for 15 h. Using phase contrast microscopy, small phase-bright amoeboid and ramified microglia were easily visible on top of the larger astrocytes that formed a confluent monolayer. The captured frames were loaded into ImageJ software as one stack, and microglia were chosen at random from each field of view and analysed for the distance migrated.
Phagocytosis of neuronal cell debris
NSC34 cells (a murine motor neuronal cell line ) were labelled with a membrane dye [1, 1'-dioctadecyl-3,3,3',3'-tetramethylindocarboxyanine perchlorate (VybrantDiI) with an emission wavelength in red-orange spectrum (Invitrogen)] according to the manufacturer's protocol. The cells were then incubated for 48 h in serum free DMEM to induce apoptosis through oxidative stress , at which point cell death had occurred in 90% of cells. The labelled NSC34 cell debris was collected and frozen at -80°C. Microglial cells plated on poly-L-lysine (Sigma) -coated 13 mm coverslips were incubated with 500 μl of labelled NSC34 cell debris for 21 h at 37°C. Microglia were extensively washed with PBS to remove any unphagocytosed debris, and immunostained with conjugated FITC-anti-mouse integrin β-1 (Biolegend) antibody. Using fluorescence microscopy, an operator blinded to the genotypes of microglial cells scored the cells according to the uptake of VybrantDiI-labelled material on a scale from 1 to 6 (Figure 4A).
Measurement of intracellular calcium concentration
The measurements of microglial intracellular free calcium were carried out according to a previously published method [68, 69]. The cells were pre-incubated with the membrane-permeable ester form of the high-affinity ratiometric calcium dye Fura-2 AM (10 μM) for 15 min and allowed to de-esterify for 30 min at room temperature (25°C). The cells were placed in a recording chamber (3 ml), which was continuously perfused (10 ml/min) with a standard extracellular solution containing: HEPES 11.6 mM, Na+129.1 mM, Cl- 143.8 mM, K+ 5.9 mM, Mg2+ 1.2 mM, Ca2+ 3.2 mM, and glucose 10.0 mM, at pH = 7.3. Fluorescent images were obtained using × 40 objective on an Axiovert 200 microscope (Carl Zeiss) fitted with a C9100 electron multiplier CCD camera (Hamamatsu Photonics) at 345/380 nm excitation (Polychrome IV, Till Photonics) and 510 nm emission filters. Devices and shutters were controlled by Openlab 3.7.1 software, which provided image acquisition and continuous online Ca2+ concentration calculation by custom scripting at 1/s. The regions of interest were defined over perinuclear/cytoplasmic regions of microglia and changes in fluorescence ratios (345/380) recorded at rest and during stimulation with specified concentrations of ATP, which was applied with a custom-made solution applicator with a solution exchange time of ~100 ms in the area of view. Background fluorescence subtraction was used and calcium concentration calculated according to Grynkiewicz .
Due to inherent differences between the two transgenic colonies of mice (transgenic SOD1 G93A and transgenic SOD1 wild type) that we observed in our past experiments, we limited our statistical comparisons to measure differences between NTG and TG cells within colonies, and not between colonies. Data were analysed using GraphPad Prism 5.0 software. All data that fitted a normal distribution were analysed using Student's t test. Data that did not fit a normal distribution were transformed using Y = Log(Y) transformation.
This study was supported by the Wellcome Trust, Medical Research Council, Motor Neuron Disease Association, University of Sheffield (Grave's Fellowship) and by British Medical Association (Vera Down Award). JG was supported by the Deutsche Forschungsgemeinschaft (DFG grant GR 1578 2-1). The authors are thankful to Dr. Benjamin Dubin-Thaler for his helpful advice regarding the spreading assay.
- Brownell B, Oppenheimer D, Hughes J: The central nervous system in motor neurone disease. J Neurol Neurosurg Psychiatry. 1970, 33: 338-357. 10.1136/jnnp.33.3.338.PubMed CentralView ArticlePubMedGoogle Scholar
- Rowland L: Diagnosis of amyotrophic lateral sclerosis. J Neurol Sci. 1998, 160 (Suppl 1): S6-24.View ArticlePubMedGoogle Scholar
- Shaw P: Molecular and cellular pathways of neurodegeneration in motor neurone disease. J Neurol Neurosurg Psychiatry. 2005, 76: 1046-1057. 10.1136/jnnp.2004.048652.PubMed CentralView ArticlePubMedGoogle Scholar
- Bruijn L, Miller T, Cleveland D: Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci. 2004, 27: 723-749. 10.1146/annurev.neuro.27.070203.144244.View ArticlePubMedGoogle Scholar
- Rosen D, Siddique T, Patterson D, Figlewicz D, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan J, Deng H: Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993, 362: 59-62. 10.1038/362059a0.View ArticlePubMedGoogle Scholar
- Andersen P, Nilsson P, Keränen M, Forsgren L, Hägglund J, Karlsborg M, Ronnevi L, Gredal O, Marklund S: Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia. Brain. 1997, 120 (Pt 10): 1723-1737.View ArticlePubMedGoogle Scholar
- Haverkamp L, Appel V, Appel S: Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995, 118 (Pt 3): 707-719.View ArticlePubMedGoogle Scholar
- Bruijn L, Becher M, Lee M, Anderson K, Jenkins N, Copeland N, Sisodia S, Rothstein J, Borchelt D, Price D, Cleveland D: ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron. 1997, 18: 327-338. 10.1016/S0896-6273(00)80272-X.View ArticlePubMedGoogle Scholar
- Gurney M, Pu H, Chiu A, Dal Canto M, Polchow C, Alexander D, Caliendo J, Hentati A, Kwon Y, Deng H: Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994, 264: 1772-1775. 10.1126/science.8209258.View ArticlePubMedGoogle Scholar
- Wong P, Borchelt D: Motor neuron disease caused by mutations in superoxide dismutase 1. Curr Opin Neurol. 1995, 8: 294-301. 10.1097/00019052-199508000-00008.View ArticlePubMedGoogle Scholar
- Clement A, Nguyen M, Roberts E, Garcia M, Boillée S, Rule M, McMahon A, Doucette W, Siwek D, Ferrante R, et al.: Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science. 2003, 302: 113-117. 10.1126/science.1086071.View ArticlePubMedGoogle Scholar
- Boillée S, Yamanaka K, Lobsiger C, Copeland N, Jenkins N, Kassiotis G, Kollias G, Cleveland D: Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006, 312: 1389-1392. 10.1126/science.1123511.View ArticlePubMedGoogle Scholar
- Beers D, Henkel J, Xiao Q, Zhao W, Wang J, Yen A, Siklos L, McKercher S, Appel S: Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2006, 103: 16021-16026. 10.1073/pnas.0607423103.PubMed CentralView ArticlePubMedGoogle Scholar
- Almer G, Teismann P, Stevic Z, Halaschek-Wiener J, Deecke L, Kostic V, Przedborski S: Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology. 2002, 58: 1277-1279.View ArticlePubMedGoogle Scholar
- Henkel J, Engelhardt J, Siklós L, Simpson E, Kim S, Pan T, Goodman J, Siddique T, Beers D, Appel S: Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol. 2004, 55: 221-235. 10.1002/ana.10805.View ArticlePubMedGoogle Scholar
- Poloni M, Facchetti D, Mai R, Micheli A, Agnoletti L, Francolini G, Mora G, Camana C, Mazzini L, Bachetti T: Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci Lett. 2000, 287: 211-214. 10.1016/S0304-3940(00)01177-0.View ArticlePubMedGoogle Scholar
- Turner M, Cagnin A, Turkheimer F, Miller C, Shaw C, Brooks D, Leigh P, Banati R: Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004, 15: 601-609. 10.1016/j.nbd.2003.12.012.View ArticlePubMedGoogle Scholar
- Troost D, Claessen N, van den Oord J, Swaab D, de Jong J: Neuronophagia in the motor cortex in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol. 1993, 19: 390-397. 10.1111/j.1365-2990.1993.tb00459.x.View ArticlePubMedGoogle Scholar
- Kawamata T, Akiyama H, Yamada T, McGeer P: Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol. 1992, 140: 691-707.PubMed CentralPubMedGoogle Scholar
- Sekizawa T, Openshaw H, Ohbo K, Sugamura K, Itoyama Y, Niland J: Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J Neurol Sci. 1998, 154: 194-199. 10.1016/S0022-510X(97)00228-1.View ArticlePubMedGoogle Scholar
- Elliott J: Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Brain Res Mol Brain Res. 2001, 95: 172-178.View ArticlePubMedGoogle Scholar
- Hemmer K, Fransen L, Vanderstichele H, Vanmechelen E, Heuschling P: An in vitro model for the study of microglia-induced neurodegeneration: involvement of nitric oxide and tumor necrosis factor-alpha. Neurochem Int. 2001, 38: 557-565. 10.1016/S0197-0186(00)00119-4.View ArticlePubMedGoogle Scholar
- Hensley K, Fedynyshyn J, Ferrell S, Floyd R, Gordon B, Grammas P, Hamdheydari L, Mhatre M, Mou S, Pye Q, et al.: Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol Dis. 2003, 14: 74-80. 10.1016/S0969-9961(03)00087-1.View ArticlePubMedGoogle Scholar
- Weydt P, Yuen E, Ransom B, Möller T: Increased cytotoxic potential of microglia from ALS-transgenic mice. Glia. 2004, 48: 179-182. 10.1002/glia.20062.View ArticlePubMedGoogle Scholar
- Yoshihara T, Ishigaki S, Yamamoto M, Liang Y, Niwa J, Takeuchi H, Doyu M, Sobue G: Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem. 2002, 80: 158-167. 10.1046/j.0022-3042.2001.00683.x.View ArticlePubMedGoogle Scholar
- Sargsyan S, Blackburn D, Barber S, Monk P, Shaw P: Mutant SOD1 G93A microglia have an inflammatory phenotype and elevated production of MCP-1. Neuroreport. 2009, 20: 1450-1455. 10.1097/WNR.0b013e328331e8fa.PubMed CentralView ArticlePubMedGoogle Scholar
- Almer G, Guégan C, Teismann P, Naini A, Rosoklija G, Hays A, Chen C, Przedborski S: Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol. 2001, 49: 176-185. 10.1002/1531-8249(20010201)49:2<176::AID-ANA37>3.0.CO;2-X.View ArticlePubMedGoogle Scholar
- Drew P, Xu J, Storer P, Chavis J, Racke M: Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders. Neurochem Int. 2006, 49: 183-189. 10.1016/j.neuint.2006.04.003.View ArticlePubMedGoogle Scholar
- Kriz J, Nguyen M, Julien J: Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2002, 10: 268-278. 10.1006/nbdi.2002.0487.View ArticlePubMedGoogle Scholar
- Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W: Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport. 2002, 13: 1067-1070. 10.1097/00001756-200206120-00018.View ArticlePubMedGoogle Scholar
- Zhu S, Stavrovskaya I, Drozda M, Kim B, Ona V, Li M, Sarang S, Liu A, Hartley D, Wu D, et al.: Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002, 417: 74-78. 10.1038/417074a.View ArticlePubMedGoogle Scholar
- Gurney M, Cutting F, Zhai P, Andrus P, Hall E: Pathogenic mechanisms in familial amyotrophic lateral sclerosis due to mutation of Cu, Zn superoxide dismutase. Pathol Biol (Paris). 1996, 44: 51-56.Google Scholar
- Ceballos-Picot I, Nicole A, Briand P, Grimber G, Delacourte A, Defossez A, Javoy-Agid F, Lafon M, Blouin J, Sinet P: Neuronal-specific expression of human copper-zinc superoxide dismutase gene in transgenic mice: animal model of gene dosage effects in Down's syndrome. Brain Res. 1991, 552: 198-214. 10.1016/0006-8993(91)90084-9.View ArticlePubMedGoogle Scholar
- Epstein C, Avraham K, Lovett M, Smith S, Elroy-Stein O, Rotman G, Bry C, Groner Y: Transgenic mice with increased Cu/Zn-superoxide dismutase activity: animal model of dosage effects in Down syndrome. Proc Natl Acad Sci USA. 1987, 84: 8044-8048. 10.1073/pnas.84.22.8044.PubMed CentralView ArticlePubMedGoogle Scholar
- Avraham K, Schickler M, Sapoznikov D, Yarom R, Groner Y: Down's syndrome: abnormal neuromuscular junction in tongue of transgenic mice with elevated levels of human Cu/Zn-superoxide dismutase. Cell. 1988, 54: 823-829. 10.1016/S0092-8674(88)91153-1.View ArticlePubMedGoogle Scholar
- Yarom R, Sapoznikov D, Havivi Y, Avraham K, Schickler M, Groner Y: Premature aging changes in neuromuscular junctions of transgenic mice with an extra human CuZnSOD gene: a model for tongue pathology in Down's syndrome. J Neurol Sci. 1988, 88: 41-53. 10.1016/0022-510X(88)90204-3.View ArticlePubMedGoogle Scholar
- Shibata N, Asayama K, Hirano A, Kobayashi M: Immunohistochemical study on superoxide dismutases in spinal cords from autopsied patients with amyotrophic lateral sclerosis. Dev Neurosci. 1996, 18: 492-498. 10.1159/000111445.View ArticlePubMedGoogle Scholar
- Deng H, Shi Y, Furukawa Y, Zhai H, Fu R, Liu E, Gorrie G, Khan M, Hung W, Bigio E, et al.: Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. Proc Natl Acad Sci USA. 2006, 103: 7142-7147. 10.1073/pnas.0602046103.PubMed CentralView ArticlePubMedGoogle Scholar
- Ezzi S, Urushitani M, Julien J: Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J Neurochem. 2007, 102: 170-178. 10.1111/j.1471-4159.2007.04531.x.View ArticlePubMedGoogle Scholar
- Hanisch U, Kettenmann H: Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007, 10: 1387-1394. 10.1038/nn1997.View ArticlePubMedGoogle Scholar
- Nimmerjahn A, Kirchhoff F, Helmchen F: Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005, 308: 1314-1318. 10.1126/science.1110647.View ArticlePubMedGoogle Scholar
- Davalos D, Grutzendler J, Yang G, Kim J, Zuo Y, Jung S, Littman D, Dustin M, Gan W: ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci. 2005, 8: 752-758. 10.1038/nn1472.View ArticlePubMedGoogle Scholar
- Raivich G, Haas S, Werner A, Klein M, Kloss C, Kreutzberg G: Regulation of MCSF receptors on microglia in the normal and injured mouse central nervous system: a quantitative immunofluorescence study using confocal laser microscopy. J Comp Neurol. 1998, 395: 342-358. 10.1002/(SICI)1096-9861(19980808)395:3<342::AID-CNE6>3.0.CO;2-2.View ArticlePubMedGoogle Scholar
- van Rossum D, Hanisch U: Microglia. Metab Brain Dis. 2004, 19: 393-411.View ArticlePubMedGoogle Scholar
- Capani F, Ellisman M, Martone M: Filamentous actin is concentrated in specific subpopulations of neuronal and glial structures in rat central nervous system. Brain Res. 2001, 923: 1-11. 10.1016/S0006-8993(01)03189-4.View ArticlePubMedGoogle Scholar
- Nolte C, Möller T, Walter T, Kettenmann H: Complement 5a controls motility of murine microglial cells in vitro via activation of an inhibitory G-protein and the rearrangement of the actin cytoskeleton. Neuroscience. 1996, 73: 1091-1107. 10.1016/0306-4522(96)00106-6.View ArticlePubMedGoogle Scholar
- Dibaj P, Steffens H, Zschuntzsch J, Nadrigny F, Schomburg ED, Kirchhoff F, Neusch C: In Vivo Imaging Reveals Distinct Inflammatory Activity of CNS Microglia versus PNS Macrophages in a Mouse Model for ALS. PLoS One. 2011, 6: e17910-10.1371/journal.pone.0017910.PubMed CentralView ArticlePubMedGoogle Scholar
- Brakebusch C, Fässler R: beta 1 integrin function in vivo: adhesion, migration and more. Cancer Metastasis Rev. 2005, 24: 403-411. 10.1007/s10555-005-5132-5.View ArticlePubMedGoogle Scholar
- Breau M, Pietri T, Eder O, Blanche M, Brakebusch C, Fässler R, Thiery J, Dufour S: Lack of beta1 integrins in enteric neural crest cells leads to a Hirschsprung-like phenotype. Development. 2006, 133: 1725-1734. 10.1242/dev.02346.View ArticlePubMedGoogle Scholar
- Leone D, Relvas J, Campos L, Hemmi S, Brakebusch C, Fässler R, Ffrench-Constant C, Suter U: Regulation of neural progenitor proliferation and survival by beta1 integrins. J Cell Sci. 2005, 118: 2589-2599. 10.1242/jcs.02396.View ArticlePubMedGoogle Scholar
- Streit W, Kreutzberg G: Response of endogenous glial cells to motor neuron degeneration induced by toxic ricin. J Comp Neurol. 1988, 268: 248-263. 10.1002/cne.902680209.View ArticlePubMedGoogle Scholar
- Pearson H, Payne B, Cunningham T: Microglial invasion and activation in response to naturally occurring neuronal degeneration in the ganglion cell layer of the postnatal cat retina. Brain Res Dev Brain Res. 1993, 76: 249-255.View ArticlePubMedGoogle Scholar
- Thanos S: The Relationship of Microglial Cells to Dying Neurons During Natural Neuronal Cell Death and Axotomy-induced Degeneration of the Rat Retina. Eur J Neurosci. 1991, 3: 1189-1207. 10.1111/j.1460-9568.1991.tb00054.x.View ArticlePubMedGoogle Scholar
- Hetz C, Thielen P, Matus S, Nassif M, Court F, Kiffin R, Martinez G, Cuervo A, Brown R, Glimcher L: XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. Genes Dev. 2009, 23: 2294-2306. 10.1101/gad.1830709.PubMed CentralView ArticlePubMedGoogle Scholar
- Hsieh C, Koike M, Spusta S, Niemi E, Yenari M, Nakamura M, Seaman W: A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem. 2009, 109: 1144-1156. 10.1111/j.1471-4159.2009.06042.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Takahashi K, Prinz M, Stagi M, Chechneva O, Neumann H: TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLoS Med. 2007, 4: e124-10.1371/journal.pmed.0040124.PubMed CentralView ArticlePubMedGoogle Scholar
- Ralevic V, Burnstock G: Receptors for purines and pyrimidines. Pharmacol Rev. 1998, 50: 413-492.PubMedGoogle Scholar
- Ohsawa K, Irino Y, Nakamura Y, Akazawa C, Inoue K, Kohsaka S: Involvement of P2X4 and P2Y12 receptors in ATP-induced microglial chemotaxis. Glia. 2007, 55: 604-616. 10.1002/glia.20489.View ArticlePubMedGoogle Scholar
- Inoue K: The function of microglia through purinergic receptors: neuropathic pain and cytokine release. Pharmacol Ther. 2006, 109: 210-226. 10.1016/j.pharmthera.2005.07.001.View ArticlePubMedGoogle Scholar
- Tsuda M, Tozaki-Saitoh H, Inoue K: Pain and purinergic signaling. Brain Res Rev. 2010, 63: 222-232. 10.1016/j.brainresrev.2009.11.003.View ArticlePubMedGoogle Scholar
- Lambert C, Ase AR, Seguela P, Antel JP: Distinct migratory and cytokine responses of human microglia and macrophages to ATP. Brain Behav Immun. 2010, 24: 1241-1248. 10.1016/j.bbi.2010.02.010.View ArticlePubMedGoogle Scholar
- Inoue K: Purinergic systems in microglia. Cell Mol Life Sci. 2008, 65: 3074-3080. 10.1007/s00018-008-8210-3.View ArticlePubMedGoogle Scholar
- McLarnon J: Purinergic mediated changes in Ca2+ mobilization and functional responses in microglia: effects of low levels of ATP. J Neurosci Res. 2005, 81: 349-356. 10.1002/jnr.20475.View ArticlePubMedGoogle Scholar
- D'Ambrosi N, Finocchi P, Apolloni S, Cozzolino M, Ferri A, Padovano V, Pietrini G, Carrì M, Volonté C: The proinflammatory action of microglial P2 receptors is enhanced in SOD1 models for amyotrophic lateral sclerosis. J Immunol. 2009, 183: 4648-4656. 10.4049/jimmunol.0901212.View ArticlePubMedGoogle Scholar
- Saura J, Tusell J, Serratosa J: High-yield isolation of murine microglia by mild trypsinization. Glia. 2003, 44: 183-189. 10.1002/glia.10274.View ArticlePubMedGoogle Scholar
- Cashman N, Durham H, Blusztajn J, Oda K, Tabira T, Shaw I, Dahrouge S, Antel J: Neuroblastoma × spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Dev Dyn. 1992, 194: 209-221. 10.1002/aja.1001940306.View ArticlePubMedGoogle Scholar
- Menzies F, Cookson M, Taylor R, Turnbull D, Chrzanowska-Lightowlers Z, Dong L, Figlewicz D, Shaw P: Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain. 2002, 125: 1522-1533. 10.1093/brain/awf167.View ArticlePubMedGoogle Scholar
- Grosskreutz J, Haastert K, Dewil M, Van Damme P, Callewaert G, Robberecht W, Dengler R, Van Den Bosch L: Role of mitochondria in kainate-induced fast Ca2+ transients in cultured spinal motor neurons. Cell Calcium. 2007, 42: 59-69. 10.1016/j.ceca.2006.11.010.View ArticlePubMedGoogle Scholar
- Haastert K, Grosskreutz J, Jaeckel M, Laderer C, Bufler J, Grothe C, Claus P: Rat embryonic motoneurons in long-term co-culture with Schwann cells--a system to investigate motoneuron diseases on a cellular level in vitro. J Neurosci Methods. 2005, 142: 275-284. 10.1016/j.jneumeth.2004.09.003.View ArticlePubMedGoogle Scholar
- Grynkiewicz G, Poenie M, Tsien R: A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985, 260: 3440-3450.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.